Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics

Rhea-AI Filing Summary

Barclays PLC reports a significant ownership position in Cartesian Therapeutics Inc. (common stock). Barclays discloses that it beneficially owns 1,760,326 shares of Cartesian’s common stock, representing 5.99% of the class as of June 30, 2026.

Within this total, Barclays has sole voting powershared voting powersole dispositive powershared dispositive power

Key Figures

Beneficial ownership: 1,760,326 shares Percent of class: 5.99% Sole voting power: 1,739,724 shares +3 more

6 metrics

Beneficial ownership 1,760,326 shares Total Cartesian Therapeutics common shares beneficially owned by Barclays PLC

Percent of class 5.99% Percentage of Cartesian Therapeutics common stock class owned by Barclays PLC

Sole voting power 1,739,724 shares Shares of Cartesian Therapeutics for which Barclays PLC has sole voting power

Shared voting power 20,602 shares Shares of Cartesian Therapeutics for which Barclays PLC has shared voting power

Sole dispositive power 1,739,724 shares Shares over which Barclays PLC has sole power to dispose

Shared dispositive power 20,602 shares Shares over which Barclays PLC has shared power to dispose

Key Terms

beneficially owned, sole voting power, shared voting power, sole dispositive power, +2 more

6 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 1760326"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 1739724"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared voting power financial

"Shared power to vote or to direct the vote: 20602"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 1739724"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

shared dispositive power financial

"Shared power to dispose or to direct the disposition of: 20602"

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

FAQ

What percentage of Cartesian Therapeutics (RNAC) does Barclays PLC report owning?

Barclays PLC reports beneficial ownership of 5.99% of Cartesian Therapeutics’ common stock. This corresponds to 1,760,326 shares of RNAC common stock as of June 30, 2026, according to the Schedule 13G filing.

How many Cartesian Therapeutics (RNAC) shares does Barclays PLC beneficially own?

Barclays PLC beneficially owns 1,760,326 shares of Cartesian Therapeutics common stock. This holding represents 5.99% of the outstanding class, based on the company’s disclosure in the Schedule 13G ownership report.

What voting power does Barclays PLC have over its Cartesian Therapeutics (RNAC) shares?

Barclays PLC has sole voting power over 1,739,724 shares and shared voting power over 20,602 shares of Cartesian Therapeutics common stock, as detailed in the Schedule 13G under the ownership breakdown.

What dispositive power does Barclays PLC report for its RNAC holdings?

For Cartesian Therapeutics shares, Barclays PLC reports sole dispositive power over 1,739,724 shares and shared dispositive power over 20,602 shares, meaning these are the amounts over which it can direct disposition.

Which Barclays subsidiaries are linked to the Cartesian Therapeutics (RNAC) position?

The filing identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as subsidiaries related to the security position in Cartesian Therapeutics reported by the parent holding company Barclays PLC.

What type of security in Cartesian Therapeutics (RNAC) is Barclays PLC reporting on?

Barclays PLC is reporting ownership of COMMON-STOCK of Cartesian Therapeutics Inc. The holding covers 1,760,326 common shares with a reported 5.99% ownership of that class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 06:34 PM Accepted by SEC EDGAR 08/13/2026 - 06:34 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

CARTESIAN THERAPEUTICS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

816212302

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 816212302

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,760,326.00
6	Shared Voting Power 20,602.00
7	Sole Dispositive Power 1,760,326.00
8	Shared Dispositive Power 20,602.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,760,326.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.99 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CARTESIAN THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 7495 New Horizon Way, MD, 21703
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP Number(s): 816212302
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1760326
(b)	Percent of class: 5.99 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1739724
	(ii) Shared power to vote or to direct the vote: 20602
	(iii) Sole power to dispose or to direct the disposition of: 1739724
	(iv) Shared power to dispose or to direct the disposition of: 20602
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	08/13/2026